A Summary of the Endocrine Society Clinical Practice Guidelines on Congenital Adrenal Hyperplasia due to Steroid 21-Hydroxylase Deficiency

Steroid 21-hydroxylase deficiency accounts for about 95% of cases of congenital adrenal hyperplasia (CAH). Newborns are currently being screened for the classical forms of this disease throughout the United States and in 12 other countries. As such, it seems important to develop the best practice gu...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of pediatric endocrinology Vol. 2010; no. 1; p. 494173
Main Authors Speiser, Phyllis W, Azziz, Ricardo, Baskin, Laurence S, Ghizzoni, Lucia, Hensle, Terry W, Merke, Deborah P, Meyer-Bahlburg, Heino F L, Miller, Walter L, Montori, Victor M, Oberfield, Sharon E, Ritzen, Martin, White, Perrin C
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 04.05.2010
Subjects
Adrenogenital syndrome
Associations, institutions, etc
Care and treatment
Genetic disorders
Societies
Task forces
Online AccessGet full text

Cover

More Information
Summary:Steroid 21-hydroxylase deficiency accounts for about 95% of cases of congenital adrenal hyperplasia (CAH). Newborns are currently being screened for the classical forms of this disease throughout the United States and in 12 other countries. As such, it seems important to develop the best practice guidelines for treating not only infants and children, but affected adults as well. This report gives a brief overview of the most recent expert opinion and clinical practice guidelines for CAH as formulated by The Endocrine Society Task Force.
ISSN:1687-9856
1687-9848
1687-9856
DOI:10.1186/1687-9856-2010-494173